The following is a summary of updated recommendations and new data on COVID-19 vaccination in MS patients. (See also DMTs and vaccine response in MS: the evidence to date, NeuroSens, July 27, 2021.) Read More
ECTRIMS SPECIAL REPORT
The recently concluded European Committee on Treatment and Research in MS (ECTRIMS) annual meeting presented a number of new approaches for evaluating the efficacy of high-efficacy disease-modifying therapies. Read More
Jim is a 26-year-old firefighter who presents with an episode of mild leg weakness, sensory level at T6 and moderate bladder symptoms.
At presentation his EDSS score is 3.0, with leg weakness, spasticity and sensory changes. Baseline brain MRI reveals several (10) lesions including brain and brainstem. Spinal MRI shows a gadolinium-enhancing lesion at T2, and another lesion which does not enhance at C3.
He is treated with steroids with a good response. Serum is negative for anti-AQP4 antibodies and anti-MOG antibodies, and CSF is positive for oligoclonal banding. All other preliminary investigations are unremarkable and the MRI looks characteristic for multiple sclerosis.
At 3-month follow-up, Jim still has sensory and bladder symptoms. EDSS score is 2.0 (sensory 2, bowel 1, bladder 1).
The European Committee for Treatment and Research in MS (ECTRIMS) annual meeting presented new data that helped to clarify the mode of action of anti-CD20 agents and address some safety issues that have arisen during the COVID-19 pandemic. Read More